Verisante Technology Inc. (TSX-V:VRS) has received regulatory approval to sell its Aura skin cancer detection device in Australia – one of the world’s hotspots for skin cancer.
Verisante has already received regulatory approval to sell the Aura in Canada and Europe.
"After Canadian and European approval earlier this quarter, obtaining Australian approval completes the company's regulatory goals for 2011," said Verisante president and CEO Thomas Braun. "In Australia, access to quick, accurate information to aid skin cancer diagnoses is absolutely essential."
The Aura is an optical device that uses a spectroscopy to analyze biomarkers in human tissue. It can be used by dermatologists to scan moles and other lesions on patients to determine which should be biopsied.
According to Australia’s Department of Health, the country has the highest skin cancer incidence rate in the world – nearly four times as high as Canada’s, and 13 times the global average. Australian doctors have more than one million patient consultations per year for skin cancer.
Popular Science Magazine named Verinsate’s Aura one of the top inventions for 2011. In addition to the Aura, Verisante makes the Verisante Core, which can be used in edoscopies to scan for cancer in the stomach and lungs.
Nelson Bennett
@nbennett_biv